CNCR SEC Filings — Range Cancer Therapeutics ETF
Data updated: 2025-04-28
37 SEC filings are listed: 10 prospectuses (latest Dec 20, 2024), 20 quarterly N-PORT holdings reports (latest Apr 28, 2025), 6 annual N-CEN reports (latest Nov 14, 2023) and 1 N-CEN/A (latest Jan 10, 2025).
CNCR Prospectus (485BPOS / 497)
Objective, strategy, fees and risks. 10 filings on SEC EDGAR.
CNCR Portfolio holdings (N-PORT)
Full holdings and monthly flows, filed quarterly. 20 filings on SEC EDGAR.
- Filed Apr 28, 2025
- Filed Jan 29, 2025
- Filed Oct 25, 2024
- Filed Jul 30, 2024
- Filed Apr 26, 2024
- Filed Jan 29, 2024
- Filed Oct 30, 2023
- Filed Jul 31, 2023
- Filed Apr 26, 2023
- Filed Jan 30, 2023
- Filed Oct 28, 2022
- Filed Aug 1, 2022
- Filed Apr 28, 2022
- Filed Jan 28, 2022
- Filed Oct 28, 2021
- Filed Jul 30, 2021
- Filed Apr 27, 2021
- Filed Jan 29, 2021
- Filed Oct 27, 2020
- Filed Jul 28, 2020
CNCR Annual census (N-CEN)
Service providers, brokerage and operations. 6 filings on SEC EDGAR.
CNCR Annual census, amended (N-CEN/A) (N-CEN/A)
1 filing on SEC EDGAR.
Browse every Range Cancer Therapeutics ETF filing on SEC EDGAR
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, and annual data from Form N-CEN.
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.